company background image
TGTX

TG Therapeutics NasdaqCM:TGTX Stock Report

Last Price

US$7.98

Market Cap

US$1.1b

7D

-3.7%

1Y

-65.8%

Updated

28 Nov, 2022

Data

Company Financials +
TGTX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

TGTX Stock Overview

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

TG Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for TG Therapeutics
Historical stock prices
Current Share PriceUS$7.98
52 Week HighUS$24.90
52 Week LowUS$3.48
Beta2.11
1 Month Change39.51%
3 Month Change17.87%
1 Year Change-65.84%
3 Year Change1.79%
5 Year Change-2.09%
Change since IPO602.31%

Recent News & Updates

TG Therapeutics: Elucidating The Upcoming Binary

Oct 09

Recent updates

Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt

Sep 07
Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt

Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?

Jun 06
Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?

Rock star Growth Puts TG Therapeutics (NASDAQ:TGTX) In A Position To Use Debt

Oct 25
Rock star Growth Puts TG Therapeutics (NASDAQ:TGTX) In A Position To Use Debt

Is TG Therapeutics (NASDAQ:TGTX) Using Too Much Debt?

Jul 13
Is TG Therapeutics (NASDAQ:TGTX) Using Too Much Debt?

When Will TG Therapeutics, Inc. (NASDAQ:TGTX) Breakeven?

Apr 19
When Will TG Therapeutics, Inc. (NASDAQ:TGTX) Breakeven?

Have Insiders Been Selling TG Therapeutics, Inc. (NASDAQ:TGTX) Shares?

Feb 23
Have Insiders Been Selling TG Therapeutics, Inc. (NASDAQ:TGTX) Shares?

Do Insiders Own Lots Of Shares In TG Therapeutics, Inc. (NASDAQ:TGTX)?

Jan 19
Do Insiders Own Lots Of Shares In TG Therapeutics, Inc. (NASDAQ:TGTX)?

TG Therapeutics, Inc. (NASDAQ:TGTX) Analysts Just Slashed Next Year's Revenue Estimates By 12%

Dec 14
TG Therapeutics, Inc. (NASDAQ:TGTX) Analysts Just Slashed Next Year's Revenue Estimates By 12%

How Much Are TG Therapeutics, Inc. (NASDAQ:TGTX) Insiders Taking Off The Table?

Nov 24
How Much Are TG Therapeutics, Inc. (NASDAQ:TGTX) Insiders Taking Off The Table?

Shareholder Returns

TGTXUS BiotechsUS Market
7D-3.7%0.2%0.3%
1Y-65.8%-16.1%-20.5%

Return vs Industry: TGTX underperformed the US Biotechs industry which returned -14.4% over the past year.

Return vs Market: TGTX underperformed the US Market which returned -18.5% over the past year.

Price Volatility

Is TGTX's price volatile compared to industry and market?
TGTX volatility
TGTX Average Weekly Movement22.3%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: TGTX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 22% a week.

Volatility Over Time: TGTX's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1993186Mike Weisshttps://www.tgtherapeutics.com

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.

TG Therapeutics, Inc. Fundamentals Summary

How do TG Therapeutics's earnings and revenue compare to its market cap?
TGTX fundamental statistics
Market CapUS$1.07b
Earnings (TTM)-US$238.68m
Revenue (TTM)US$5.03m

212.6x

P/S Ratio

-4.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TGTX income statement (TTM)
RevenueUS$5.03m
Cost of RevenueUS$472.00k
Gross ProfitUS$4.55m
Other ExpensesUS$243.23m
Earnings-US$238.68m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.78
Gross Margin90.61%
Net Profit Margin-4,748.89%
Debt/Equity Ratio69.8%

How did TGTX perform over the long term?

See historical performance and comparison